727 related articles for article (PubMed ID: 29120053)
1. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice.
Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y
Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053
[TBL] [Abstract][Full Text] [Related]
2. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA Pvt1 regulates the immunosuppression activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.
Zheng Y; Tian X; Wang T; Xia X; Cao F; Tian J; Xu P; Ma J; Xu H; Wang S
Mol Cancer; 2019 Mar; 18(1):61. PubMed ID: 30925926
[TBL] [Abstract][Full Text] [Related]
4. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
[TBL] [Abstract][Full Text] [Related]
5. Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.
Yang J; Yan C; Vilgelm AE; Chen SC; Ayers GD; Johnson CA; Richmond A
Cancer Immunol Res; 2021 Feb; 9(2):200-213. PubMed ID: 33177110
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
7. MDSCs drive the process of endometriosis by enhancing angiogenesis and are a new potential therapeutic target.
Zhang T; Zhou J; Man GCW; Leung KT; Liang B; Xiao B; Ma X; Huang S; Huang H; Hegde VL; Zhong Y; Li Y; Kong GWS; Yiu AKW; Kwong J; Ng PC; Lessey BA; Nagarkatti PS; Nagarkatti M; Wang CC
Eur J Immunol; 2018 Jun; 48(6):1059-1073. PubMed ID: 29460338
[TBL] [Abstract][Full Text] [Related]
8. IL-33 inhibits the differentiation and immunosuppressive activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.
Lim HX; Choi S; Cho D; Kim TS
Immunol Cell Biol; 2017 Jan; 95(1):99-107. PubMed ID: 27507556
[TBL] [Abstract][Full Text] [Related]
9. Dual negative roles of C/EBPα in the expansion and pro-tumor functions of MDSCs.
Mackert JR; Qu P; Min Y; Johnson PF; Yang L; Lin PC
Sci Rep; 2017 Oct; 7(1):14048. PubMed ID: 29070836
[TBL] [Abstract][Full Text] [Related]
10. MMP-9-cleaved osteopontin isoform mediates tumor immune escape by inducing expansion of myeloid-derived suppressor cells.
Shao L; Zhang B; Wang L; Wu L; Kan Q; Fan K
Biochem Biophys Res Commun; 2017 Dec; 493(4):1478-1484. PubMed ID: 28986261
[TBL] [Abstract][Full Text] [Related]
11. Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment.
Sceneay J; Griessinger CM; Hoffmann SHL; Wen SW; Wong CSF; Krumeich S; Kneilling M; Pichler BJ; Möller A
PLoS One; 2018; 13(4):e0196040. PubMed ID: 29677215
[TBL] [Abstract][Full Text] [Related]
12. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
[TBL] [Abstract][Full Text] [Related]
13. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
Alissafi T; Hatzioannou A; Mintzas K; Barouni RM; Banos A; Sormendi S; Polyzos A; Xilouri M; Wielockx B; Gogas H; Verginis P
J Clin Invest; 2018 Aug; 128(9):3840-3852. PubMed ID: 29920188
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of Ly6G
Heim CE; West SC; Ali H; Kielian T
Infect Immun; 2018 Dec; 86(12):. PubMed ID: 30249747
[TBL] [Abstract][Full Text] [Related]
15. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
16. Surgery-induced monocytic myeloid-derived suppressor cells expand regulatory T cells in lung cancer.
Wang J; Yang L; Yu L; Wang YY; Chen R; Qian J; Hong ZP; Su XS
Oncotarget; 2017 Mar; 8(10):17050-17058. PubMed ID: 28178645
[TBL] [Abstract][Full Text] [Related]
17. The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury.
Zhang C; Wang S; Li J; Zhang W; Zheng L; Yang C; Zhu T; Rong R
Cell Death Dis; 2017 Mar; 8(3):e2695. PubMed ID: 28333137
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients.
Jordan KR; Kapoor P; Spongberg E; Tobin RP; Gao D; Borges VF; McCarter MD
Cancer Immunol Immunother; 2017 Apr; 66(4):503-513. PubMed ID: 28108766
[TBL] [Abstract][Full Text] [Related]
19. The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling.
Mohamed E; Sierra RA; Trillo-Tinoco J; Cao Y; Innamarato P; Payne KK; de Mingo Pulido A; Mandula J; Zhang S; Thevenot P; Biswas S; Abdalla SK; Costich TL; Hänggi K; Anadon CM; Flores ER; Haura EB; Mehrotra S; Pilon-Thomas S; Ruffell B; Munn DH; Cubillos-Ruiz JR; Conejo-Garcia JR; Rodriguez PC
Immunity; 2020 Apr; 52(4):668-682.e7. PubMed ID: 32294407
[TBL] [Abstract][Full Text] [Related]
20. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]